Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Conference Participants

doi:10.1016/j.kint.2018.10.018

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Conference Participants

Medicine - Renal and Hypertension Division

Research output: Contribution to journal › Article › peer-review

195 Scopus citations

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

Original language	English (US)
Pages (from-to)	268-280
Number of pages	13
Journal	Kidney international
Volume	95
Issue number	2
DOIs	https://doi.org/10.1016/j.kint.2018.10.018
State	Published - Feb 2019

Bibliographical note

Funding Information:
JF declared having received consultancy fees from Amgen, Alnylam, Bayer, Boehringer Ingelheim, Calliditas, Inositec, Novo Nordisk, Omeros, and Vifor; speaker honoraria from Amgen and Vifor; and travel support from Boehringer Ingelheim. DCC declared having received consultancy fees from Alnylam, Calliditas, ChemoCentryx, Dimerix, Mallinckrodt, Novartis, and Rigel; and research support from Genentech and National Institute of Diabetes, Digestive, and Kidney Diseases. JJH declared having received consultancy fees from Aurinia, Dimerix, and Variant. PHN declared having received research support from Immune Tolerance Network. SCWT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Sanofi. JFMW declared having received research support from Dutch Kidney Foundation and European Union FP7 programme (EUrenOmics); and future research support from Achillion and ChemoCentryx. DCW declared having received consultancy fees from Akebia, AstraZeneca, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. BHR declared having received consultancy fees from Alexion, Aurinia, Biogen, Biomarin, Bristol-Myers Squibb, ChemoCentryx, EMD Serono, Frazier Life Sciences, Genentech, Gilead, Lupus Foundation of America, Mallinckrodt, MedImmune, Novartis, Pharmalink, Ra Pharmaceuticals, Retrophin, and Rigel; and travel support from American Society of Nephrology, Aurinia, Biogen, Budapest Nephrology School, Childhood Arthritis and Rheumatology Research Alliance, ChemoCentryx, Congress on SLE (Australia), Central Society for Clinical and Translational Research-Midwestern American Federation for Medical Research, CureGN, European League Against Rheumatism Congress and Portuguese Congress, KDIGO, MENTOR (Multicenter Randomized Controlled Trial of Rituximab), Office of Minority Health Impact for Lupus, Pharmalink, Ra Pharmaceuticals, Retrophin, and UpToDate. All other authors declared no competing interests.

Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma.

Publisher Copyright:
© 2019 The Author(s)

Keywords

IgA nephropathy
KDIGO
hypertension
kidney biopsy
membranous nephropathy
proteinuria

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.kint.2018.10.018

OpenUrl availability

Full text

Cite this

@article{96af08e3d1ef480b8fbe89f14a3ed610,

title = "Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",

abstract = "The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.",

keywords = "IgA nephropathy, KDIGO, hypertension, kidney biopsy, membranous nephropathy, proteinuria",

author = "{Conference Participants} and J{\"u}rgen Floege and Barbour, {Sean J.} and Cattran, {Daniel C.} and Hogan, {Jonathan J.} and Tang, {Sydney C.W.} and Patrick Nachman and Michael Cheung and Wheeler, {David C.} and Winkelmayer, {Wolfgang C.} and Rovin, {Brad H.} and Adler, {Sharon G.} and Alpers, {Charles E.} and Isabelle Ayoub and Arvind Bagga and Jonathan Barratt and Caster, {Dawn J.} and Chan, {Daniel T.M.} and Anthony Chang and Choo, {Jason Chon Jun} and Cook, {H. Terence} and Rosanna Coppo and Fervenza, {Fernando C.} and Fogo, {Agnes B.} and Fox, {Jonathan G.} and Gibson, {Keisha L.} and Glassock, {Richard J.} and David Harris and Hodson, {Elisabeth M.} and Elion Hoxha and Kunitoshi Iseki and Jennette, {J. Charles} and Vivekanand Jha and Johnson, {David W.} and Shinya Kaname and Ritsuko Katafuchi and Kitching, {A. Richard} and Lafayette, {Richard A.} and Li, {Philip K.T.} and Adrian Liew and Jicheng Lv and Ana Malvar and Shoichi Maruyama and Mej{\'i}a-Vilet, {Juan Manuel} and Moeller, {Marcus J.} and Mok, {Chi Chiu} and Nester, {Carla M.} and Eisei Noiri and O'Shaughnessy, {Michelle M.} and Seza {\"O}zen",

note = "Funding Information: JF declared having received consultancy fees from Amgen, Alnylam, Bayer, Boehringer Ingelheim, Calliditas, Inositec, Novo Nordisk, Omeros, and Vifor; speaker honoraria from Amgen and Vifor; and travel support from Boehringer Ingelheim. DCC declared having received consultancy fees from Alnylam, Calliditas, ChemoCentryx, Dimerix, Mallinckrodt, Novartis, and Rigel; and research support from Genentech and National Institute of Diabetes, Digestive, and Kidney Diseases. JJH declared having received consultancy fees from Aurinia, Dimerix, and Variant. PHN declared having received research support from Immune Tolerance Network. SCWT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Sanofi. JFMW declared having received research support from Dutch Kidney Foundation and European Union FP7 programme (EUrenOmics); and future research support from Achillion and ChemoCentryx. DCW declared having received consultancy fees from Akebia, AstraZeneca, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. BHR declared having received consultancy fees from Alexion, Aurinia, Biogen, Biomarin, Bristol-Myers Squibb, ChemoCentryx, EMD Serono, Frazier Life Sciences, Genentech, Gilead, Lupus Foundation of America, Mallinckrodt, MedImmune, Novartis, Pharmalink, Ra Pharmaceuticals, Retrophin, and Rigel; and travel support from American Society of Nephrology, Aurinia, Biogen, Budapest Nephrology School, Childhood Arthritis and Rheumatology Research Alliance, ChemoCentryx, Congress on SLE (Australia), Central Society for Clinical and Translational Research-Midwestern American Federation for Medical Research, CureGN, European League Against Rheumatism Congress and Portuguese Congress, KDIGO, MENTOR (Multicenter Randomized Controlled Trial of Rituximab), Office of Minority Health Impact for Lupus, Pharmalink, Ra Pharmaceuticals, Retrophin, and UpToDate. All other authors declared no competing interests. Funding Information: The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma. Publisher Copyright: {\textcopyright} 2019 The Author(s)",

year = "2019",

month = feb,

doi = "10.1016/j.kint.2018.10.018",

language = "English (US)",

volume = "95",

pages = "268--280",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Management and treatment of glomerular diseases (part 1)

T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

AU - Conference Participants

AU - Floege, Jürgen

AU - Barbour, Sean J.

AU - Cattran, Daniel C.

AU - Hogan, Jonathan J.

AU - Tang, Sydney C.W.

AU - Nachman, Patrick

AU - Cheung, Michael

AU - Wheeler, David C.

AU - Winkelmayer, Wolfgang C.

AU - Rovin, Brad H.

AU - Adler, Sharon G.

AU - Alpers, Charles E.

AU - Ayoub, Isabelle

AU - Bagga, Arvind

AU - Barratt, Jonathan

AU - Caster, Dawn J.

AU - Chan, Daniel T.M.

AU - Chang, Anthony

AU - Choo, Jason Chon Jun

AU - Cook, H. Terence

AU - Coppo, Rosanna

AU - Fervenza, Fernando C.

AU - Fogo, Agnes B.

AU - Fox, Jonathan G.

AU - Gibson, Keisha L.

AU - Glassock, Richard J.

AU - Harris, David

AU - Hodson, Elisabeth M.

AU - Hoxha, Elion

AU - Iseki, Kunitoshi

AU - Jennette, J. Charles

AU - Jha, Vivekanand

AU - Johnson, David W.

AU - Kaname, Shinya

AU - Katafuchi, Ritsuko

AU - Kitching, A. Richard

AU - Lafayette, Richard A.

AU - Li, Philip K.T.

AU - Liew, Adrian

AU - Lv, Jicheng

AU - Malvar, Ana

AU - Maruyama, Shoichi

AU - Mejía-Vilet, Juan Manuel

AU - Moeller, Marcus J.

AU - Mok, Chi Chiu

AU - Nester, Carla M.

AU - Noiri, Eisei

AU - O'Shaughnessy, Michelle M.

AU - Özen, Seza

N1 - Funding Information: JF declared having received consultancy fees from Amgen, Alnylam, Bayer, Boehringer Ingelheim, Calliditas, Inositec, Novo Nordisk, Omeros, and Vifor; speaker honoraria from Amgen and Vifor; and travel support from Boehringer Ingelheim. DCC declared having received consultancy fees from Alnylam, Calliditas, ChemoCentryx, Dimerix, Mallinckrodt, Novartis, and Rigel; and research support from Genentech and National Institute of Diabetes, Digestive, and Kidney Diseases. JJH declared having received consultancy fees from Aurinia, Dimerix, and Variant. PHN declared having received research support from Immune Tolerance Network. SCWT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Sanofi. JFMW declared having received research support from Dutch Kidney Foundation and European Union FP7 programme (EUrenOmics); and future research support from Achillion and ChemoCentryx. DCW declared having received consultancy fees from Akebia, AstraZeneca, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. BHR declared having received consultancy fees from Alexion, Aurinia, Biogen, Biomarin, Bristol-Myers Squibb, ChemoCentryx, EMD Serono, Frazier Life Sciences, Genentech, Gilead, Lupus Foundation of America, Mallinckrodt, MedImmune, Novartis, Pharmalink, Ra Pharmaceuticals, Retrophin, and Rigel; and travel support from American Society of Nephrology, Aurinia, Biogen, Budapest Nephrology School, Childhood Arthritis and Rheumatology Research Alliance, ChemoCentryx, Congress on SLE (Australia), Central Society for Clinical and Translational Research-Midwestern American Federation for Medical Research, CureGN, European League Against Rheumatism Congress and Portuguese Congress, KDIGO, MENTOR (Multicenter Randomized Controlled Trial of Rituximab), Office of Minority Health Impact for Lupus, Pharmalink, Ra Pharmaceuticals, Retrophin, and UpToDate. All other authors declared no competing interests. Funding Information: The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Achillion, Aurinia Pharmaceuticals, Calliditas Therapeutics, ChemoCentryx, Chugai, Expedition Therapeutics, Gilead, Goldfinch Bio, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Novartis, Omeros, Sanofi Genzyme, and Vifor Fresenius Medical Care Renal Pharma. Publisher Copyright: © 2019 The Author(s)

PY - 2019/2

Y1 - 2019/2

N2 - The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

AB - The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

KW - IgA nephropathy

KW - KDIGO

KW - hypertension

KW - kidney biopsy

KW - membranous nephropathy

KW - proteinuria

UR - http://www.scopus.com/inward/record.url?scp=85059848558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059848558&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2018.10.018

DO - 10.1016/j.kint.2018.10.018

M3 - Article

C2 - 30665568

AN - SCOPUS:85059848558

SN - 0085-2538

VL - 95

SP - 268

EP - 280

JO - Kidney international

JF - Kidney international

IS - 2

ER -

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this